Uncategorized

IRVINE, Calif., Oct. 24, 2019 /PRNewswire/ — AIVITA Biomedical, Inc., a biotech company specializing in innovative stem cell applications, announced today updated data from its ongoing glioblastoma Phase 2 clinical trial investigating AIVITA’s platform immunotherapy targeting tumor-initiating cells. In approximately 80% of treated patients, sequential blood plasma biomarker analyses have identified the induction of a […]

New Comparison Indicates Superior Survival IRVINE, Calif., Oct. 17, 2019 /PRNewswire/ — AIVITA Biomedical, Inc., a biotechnology company specializing in innovative stem cell applications, announced the publication of an article titled “Survival Comparison between Melanoma Patients Treated with Patient-Specific Dendritic Cell Vaccines and Other Immunotherapies Based on Extent of Disease at the Time of Treatment“ in

IRVINE, Calif., July 8, 2019 /PRNewswire/ — AIVITA Biomedical, Inc., a biotech company specializing in innovative stem cell applications, announced today new clinical data from its ongoing glioblastoma Phase 2 clinical trial, investigating AIVITA’s platform immunotherapy targeting cancer stem cells. Blood plasma biomarker analyses have identified predictive markers of efficacy in seven of eight treated

ANAHEIM, Calif.–(BUSINESS WIRE)– ClearFlow, Inc., a medical device company based in Anaheim, California, has announced that positive clinical trial results of its PleuraFlow® device were presented at the American Association for Thoracic Surgery (AATS) 99th Annual meeting on May 4 in Toronto, Canada. This new data stems from a trial evaluating the use of ClearFlow’s PleuraFlow®Active Clearance Technology® (ACT®) System

IRVINE, Calif., June 3, 2019 /PRNewswire/ — AIVITA Biomedical, Inc., a biotech company specializing in innovative stem cell applications, announced today that Chief Medical Officer Dr. Robert O. Dillman presented clinical data on melanoma patients treated with patient-specific vaccines on June 1 at the 55th Annual Meeting of ASCO in Chicago, Illinois. The data is being

AIVITA Identifies Mechanism to Enhance Patient Response Rate to Next Generation Cancer Stem Cell Immunotherapy   Findings suggest a combination with checkpoint inhibitors will enhance response rate beyond 72% survival, and facilitate a new Phase 1B approval   IRVINE, Calif., Feb. 12, 2019 /PRNewswire/ — AIVITA Biomedical, Inc., a biotech company specializing in innovative stem cell

  #MariaDB momentum is heating up! @computerworlduk lists #MariaDB as one of the hottest enterprise tech startups in the world. http://ow.ly/I7fU30nAud5   Who are the hottest enterprise tech startups in the world? MariaDB as an open source database contender made the list by Computerworld UK. http://ow.ly/I7fU30nAud5   The hottest enterprise tech startups to watch in 2019  

Philips Recognized by Frost & Sullivan for Its Integrated Medication Adherence System, PMAS NEWS PROVIDED BY Frost & Sullivan  08:00 ET By connecting patients, pharmacists, caregivers, and providers, the PMAS delivers patient care in a decentralized format SANTA CLARA, Calif., Dec. 5, 2018 /PRNewswire/ — Based on its recent analysis of the North American medication adherence market, Frost

ROOT OF SKIN™ Skincare Line Sells Out at Product Launch on QVC Japan IRVINE, Calif., Nov. 28, 2018 /PRNewswire/ — AIVITA Biomedical, Inc., a biotech company specializing in innovative stem cell applications, announced today that the Company’s revolutionary stem-cell based ROOT OF SKIN™ skincare line sold out at launch on the Japanese home shopping channel QVC Japan.

AIVITA Biomedical Consumer Skincare Line ROOT OF SKIN™ to Be Sold on Home Shopping Channel QVC Japan IRVINE, Calif., Oct. 30, 2018 /PRNewswire/ — AIVITA Biomedical, Inc., a biotech company specializing in innovative stem cell applications, announced today it has executed a deal to sell the Company’s ROOT OF SKIN™ line of rejuvenating skincare products